Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.gennexlab.com | |
Market Cap | 367.56 Cr. | |
Enterprise Value(EV) | 389.43 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.27 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 59.34 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 41.15 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 7.12 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 2.25 | Calculated using Price: 16.05 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 22.90 Cr. | 229,009,534 Shares |
FaceValue | 1 | |
About Gennex Laboratories Ltd. | ||
Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements. |
1 Day |
|
+2.62% |
1 Week |
|
-7.71% |
1 Month |
|
-4.69% |
3 Month |
|
-14.54% |
6 Month |
|
+27.58% |
1 Year |
|
+162.25% |
2 Year |
|
+98.15% |
5 Year |
|
+568.75% |
10 Year |
|
+1984.42% |
7 years | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 8.74 | 2.67 | 6.77 | 5.34 | 10.71 | 9.39 | 7.95 | |
Return on Capital Employed (%) | 10.91 | 6.31 | 10.52 | 8.36 | 13.24 | 11.82 | 10.19 | |
Return on Assets (%) | 5.5 | 1.68 | 4.35 | 3.42 | 6.97 | 6.18 | 4.92 |
Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 31 | 32 | 34 | 36 | 40 | 44 | 80 | 87 | |
Non Curr. Liab. | 1 | 1 | 1 | 0 | 0 | 16 | 17 | ||
Curr. Liab. | 17 | 18 | 17 | 21 | 19 | 24 | 30 | 23 | |
Minority Int. | 6 | 6 | |||||||
Equity & Liab. | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 132 | |
Non Curr. Assets | 23 | 23 | 23 | 22 | 23 | 21 | 84 | 67 | |
Curr. Assets | 26 | 28 | 29 | 35 | 36 | 47 | 49 | 65 | |
Misc. Exp. not W/O | |||||||||
Total Assets | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 132 |
Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 42 | 44 | 56 | 56 | 60 | 61 | 66 | 71 | |
Other Income | 0 | 1 | 1 | 1 | 1 | 1 | 4 | 0 | |
Total Income | 42 | 45 | 57 | 57 | 60 | 63 | 70 | 71 | |
Total Expenditure | -37 | -42 | -52 | -52 | -53 | -56 | -61 | -53 | |
PBIDT | 5 | 3 | 5 | 4 | 7 | 7 | 9 | 17 | |
Interest | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -3 | |
Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | |
Taxation | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -3 | |
Exceptional Items | 0 | 0 | 0 | ||||||
PAT | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 10 | |
Minority Interest | |||||||||
Share Associate | |||||||||
Other Related Items | 0 | 1 | |||||||
Consolidated Net Profit | 3 | 1 | 2 | 2 | 4 | 4 | 6 | 10 | |
Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 3 | 2 | -2 | -1 | 12 | 24 | |
Cash Fr. Inv. | -1 | -1 | -1 | 0 | 0 | -2 | -38 | |
Cash Fr. Finan. | 1 | -2 | 1 | 0 | 2 | -2 | 21 | |
Net Change | 0 | 0 | 2 | -2 | 0 | 8 | 6 | |
Cash & Cash Eqvt | 1 | 1 | 3 | 1 | 1 | 9 | 15 |
Fri, 29 Mar 2024
Closure of Trading Window Notice is hereby given that in pursuance of SEBI (PIT) Regulations 2015 and Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Insiders the Trading Window for dealing in the securities of the Company shall remain closed from April 01 2024 till 48 hours after the public announcement through Board of Directors in their Meeting held for announcing the Audited Financial Results for the Quarter and Year ended March 31 2024 along with other matters for which Trading Window is required to closed.The Board Meeting date to approve the audited financial results of the Company for the Quarter and Year ending on March 31 2024 will be informed in due course.All Promoters / designated / connected persons are advised not to trade in the securities of the Company during the aforesaid period of Closure of Trading Window.We request you to take the above information on record and acknowledge the receipt of the same. |
Fri, 16 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 47 of SEBI (LODR). 2015 please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the quarter and Nine Months Ended December 31 2023 announced by the Board of Directors in its meeting held on Wednesday February 14 2024. Financial Results had been published in both Business Standard (English) and Saksham (Telugu - Local) on Friday February 16 2024.We request you to take the above information on record and acknowledge the receipt of the same. |
Wed, 14 Feb 2024
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On 14.02.2024 - Scrip Code: 531739/GENNEX In just concluded Meeting of Board of Directors the Board Approved and considered the following items:1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31 2023 (annexed herewith); 2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31 2023 (annexed here with);3. Acceptance of Resignation of Mr. Tiruvarur Muralidharan Gopalakrishnan Whole time Director of the Company;4. Appointment of Dr. S.CH. DHARMA RAO as Additional Director (Non-Executive - Non Independent Director) of the Company.We hereby submit that the Board Meeting had commenced at 04:00 PM and concluded at 05:00 PM.This intimation is also uploaded on the Company website: www.gennexlab.comWe request you to take the above information on record and acknowledge the receipt of the same. |
Tue, 16 Apr 2024 |
High Decrease in 3 Months |
High Increase in 6 Months |
High Increase in 1 Year |
High Increase in 2 Years |
High Increase in 5 Years |